A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

Inclusion Criteria: * Diagnosis of primary membranous nephropathy (pMN) according to renal biopsy prior to or during screening * Screening urinary protein-to-creatinine ratio (UPCR) \>= 5 g/g from 24-hour urine collection after best supportive care for \>= 3 months prior to screening or screening UPCR \>= 4 g/g after best supportive care for \>= 6 months prior to screening * eGFR \>= 40 mL/min/1.73m\^2 or qualified endogenous creatinine clearance \>= 40 mL/min/1.73m\^2 based on 24-hour urine collection during screening * Other inclusion criteria may apply Exclusion Criteria: * Participants with a secondary cause of MN * Pregnancy or breastfeeding * Evidence of \>= 50% reduction in proteinuria during the previous 6 months prior to randomization * Severe renal impairment, including the need for dialysis or renal replacement therapy * Type 1 or 2 diabetes mellitus * Receipt of an excluded therapy, including any anti-CD20 therapy less than 9 months prior to or during screening; or cyclophosphamide, tacrolimus, or cyclosporin less than 6 months prior to or during screening * Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude participant participation * Known active infection of any kind or recent major episode of infection * Major surgery requiring hospitalization within the 4 weeks prior to screening * Current active alcohol or drug abuse or history of alcohol or drug abuse within 12 months prior to screening * Intolerance or contraindication to study therapies * Other exclusion criteria may apply